Dublin – (work wire) – “Food Allergy Market Size and Trends Report Including Analysis of Marketed Drugs and Pipelines, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecasts, 2020-2030” has been added to ResearchAndMarkets.com Show.
A food allergy is defined as an opposite immune response to a food. While any food can cause an adverse reaction, eight types of food allergens account for about 90% of all reactions: eggs, milk, peanuts, tree nuts, fish, shellfish, wheat, and soybeans.
Food-induced allergic disorders are broadly classified to cell-mediated (non-IgE-mediated) immunoglobulin E (IgE), or both IgE- and cell-mediated (mixed IgE- and non-IgE-mediated) mechanisms. IgE-mediated allergic responses are the most common type of food allergy, with rapid onset of symptoms after ingestion
For the scope of this report, the publisher will use the IgE-mediated taxonomy and will focus primarily on this taxonomy throughout.
Current treatment options consist of medications taken after accidental exposure to the allergen, with nothing intended to treat patients for allergies.
Treatment options vary based on the severity of the reaction. Antihistamines are used for mild to moderate reactions and epinephrine is used for severe reactions or anaphylaxis.
The food allergy market lacks a therapeutic agent, and the only treatments available are antihistamines or the use of epinephrine for accidental exposure.
A total of 10 of the 12 therapeutic classes in development are first-in-class drugs that introduce novel mechanisms of action for food allergy, including immunoglobulin E (IgE) inhibitors, desensitizing immunotherapy (allergens), interleukin inhibitors, anti-inflammatories, and proton tyrosine. BTK inhibitor, sphingosine-1-phosphate receptor agonist, lanthionine synthetase c-like protein 2 (LANCL2) agonist, mast cell stabilizer, and glucocorticoid receptor agonist.
The biggest unmet needs in the food allergy market are more treatment options, better drugs with fewer side effects, a lack of data, limited access, and better education.
Although there are 31 pipeline agents, large unmet needs are expected to remain, presenting an opportunity for developers in the food allergy market.
The peanut allergy market is the most valuable segment in a food allergy due to sales of Palforzia and Viaskin Peanut.
Viaskin Peanut is expected to be the most profitable food allergy drug with sales of up to $1.5 billion by 2030.
An overview of diabetes mellitus including etiology, pathophysiology, symptoms, diagnosis and treatment guidelines
Key topics covered include current treatment, pipeline treatments, trends, clinical trials, unmet needs, challenges and opportunities, and market analysis.
Analysis of the current and future market competition in the FA Therapeutics Market
Reasons to buy
The report will enable you to:
Develop and design internal and external licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the strongest pipelines
Develop business strategies by understanding the trends shaping and driving the FA Therapeutics market
Drive revenue by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FA market in the future
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage
Tracking Pharmaceutical Sales in FA Therapeutics Market from 2020-2030
Organize your sales and marketing efforts by identifying market categories and sectors that offer the most opportunities for consolidation, investments and strategic partnerships
Main topics covered:
1. Executive Summary
2 Overview of the disease
4 clinical trials
4.1 Clinical trials of food allergy
4.2 Clinical trials of food allergy by region
4.3 Clinical trials of food allergy by major sponsors
4.4 Clinical trials of food allergy – challenges
4.5 Food Allergy Clinical Trials – Opportunities
5 marketed products
5.1 IgE-mediated products
5.2 Palforzia – Product Profile
5.3 Palforzia – KOL . Views
5.4 Palforsia – Strengths and Weaknesses
5.5 Antihistamines – KOL . Perspectives
5.6 Antihistamines – Strengths and Weaknesses
5.7 Epinephrine – KOL . Perspectives
5.8 Epinephrine – Strengths and Weaknesses
5.9 Oral Immunotherapy – KOL . Perspectives
5.10 Oral Immunotherapy – Strengths and Weaknesses
5.11 Nalcrom – Product Profile
6 pipeline products
6.1 Pipeline products by type and stage
6.2 Pipeline products by therapeutic category
6.3 Pipeline products by management and innovation path
6.4 Pipeline drugs: IgE inhibitors
6.5 Pipeline drugs: desensitizing immunotherapy
6.6 Pipeline Drugs: Interleukin Inhibitors
6.7 Pipeline drugs: other
7 market analysis
7.1 Immunoglobulin E-mediated Food Market Analysis and Forecast
7.2 Latest deals in food allergy
7.3 Latest deals in the field of peanut allergy
7.3 Latest deals in eosinophilic esophagitis field
8 Opportunities, challenges, and unmet needs
8.1 Global Food Allergy Market – Challenges and Opportunities
8.2 Global Food Allergy Remedies Unmet Needs – Gap Analysis
8.3 Impact of COVID-19 on food allergy: KOL . perspectives
8 main players
10 Contact the publisher
For more information on this report, visit https://www.researchandmarkets.com/r/jfvlbj